Search
We work extensively with pharmaceutical, bioscience, medical device, academic, and other research entities on licensing, collaboration, and commercial transactions involving products and technologies at all stages of the product life cycle and the company’s development. Our diversity and breadth of experience, deep industry knowledge, and understanding of the interplay of economic, governance, regulatory, and intellectual property issues enable us to provide comprehensive advice and anticipate the array of issues that may arise.
In a highly regulated industry such as life sciences, easy access to regulatory lawyers to advise on these arrangements is critical. We draw on the depth of our life sciences practice and work seamlessly with our regulatory experts to provide unparalleled transaction support.
We work with you to structure collaborations and commercial transactions that achieve your business goals.
A global technology company on its joint venture with a global pharma company to enable the research, development and commercialization of bioelectronic medicines.
AmerisourceBergen Corporation on its $6.47bn acquisition of Alliance Healthcare from Walgreen Boots Alliance and all associated commercial transactional agreements.
Intellia Therapeutics in the launch of a new autologous and allogeneic universal CAR-T cell therapy company in collaboration with Blackstone Life Sciences and Cellex Cell Professionals GmbH, the parent company of GEMoaB.
Daiichi Sankyo on multiple transactions, including its collaboration with AstraZeneca to develop and commercialize Daiichi Sankyo’s DS-1062, a potential treatment for multiple tumor types.
BMS on its in-license from Rockefeller University of monoclonal antibodies for the treatment of COVID-19.
Gilead Sciences, Inc. on multiple transactions, including its collaboration with Dragonfly Therapeutics to develop natural killer cell engagers in oncology and inflammation.
Morphosys Ag in the drafting and negotiating of an agreement regarding the co-development and co-marketing as well as the out-licensing (ex-U.S.) of its blood cancer product.
Novartis on multiple transactions, including its COVID-19 and SIV vaccine arrangements with GSK, Roche and CureVac.
Merck KGaAon its up to €1bn immuno-oncology collaboration with F-Star.
SymBio Pharmaceuticals on various licensing arrangements with counterparties in the U.S. and in Europe.
